(Pic Courtesy: UNITAID)
In spite of an estimated 500,000 new annual cases of children with tuberculosis (TB), there are no appropriate medicines for them, UNITAID and the TB Alliance warn. With no alternatives available, treatment providers for children are forced to adapt medicines for adults as best they can, such as by cutting pills. This leads to improper treatment, treatment failure, spread of this highly-contagious disease, and conditions ripe for the development of drug-resistant strains of the bacteria.
In response to this need, UNITAID is funding a TB Alliance project to better understand the barriers that manufacturers will have to overcome to enter the pediatric TB market and to work with those manufacturers to ensure that a correctly-dosed child-friendly formulation of existing first-line TB drugs will be available in a timely manner. This work will also help speed the development of other novel regimens for children that are now in the pipeline.
TB, one of the world's most neglected diseases with almost no new treatments developed in the past 50 years, is one of the top ten causes of childhood death.It mostly affects the world's poorest, among those, the most vulnerable are children.
Denis Broun, Executive Director of UNITAID says,"Despite the world's capabilities to address this disease, pediatric tuberculosis has been ignored for far too long, resulting in a complete lack of appropriate medicines. This project is designed to spur innovation so that the right kinds of treatments are available as quickly as possible and at affordable prices. We now need other global players to also step up, especially for identifying those children affected."
The extent of the childhood TB pandemic is not fully understood. Most experts believe that TB in children goes largely undiagnosed and that the true scope of the problem is far higher than the estimates today.
